Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Evaluating combinations of diagnostic tests to discriminate different dementia types

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Accessibility of cortical regions to focal TES: Dependence on spatial position, safety, and practical constraints

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neuroimaging Of Cold Allodynia Reveals A Central Disinhibition Mechanism Of Pain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Thilo van Eimeren
  • Angelo Antonini
  • Daniela Berg
  • Nico Bohnen
  • Roberto Ceravolo
  • Alexander Drzezga
  • Günter U Höglinger
  • Makoto Higuchi
  • Stephane Lehericy
  • Simon Lewis
  • Oury Monchi
  • Peter Nestor
  • Matej Ondrus
  • Nicola Pavese
  • María Cecilia Peralta
  • Paola Piccini
  • José Ángel Pineda-Pardo
  • Irena Rektorová
  • María Rodríguez-Oroz
  • Axel Rominger
  • Klaus Seppi
  • A Jon Stoessl
  • Alessandro Tessitore
  • Stephane Thobois
  • Valtteri Kaasinen
  • Gregor Wenning
  • Hartwig R Siebner
  • Antonio P Strafella
  • James B Rowe
Vis graf over relationer

Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.

Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.

Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).

Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

OriginalsprogEngelsk
TidsskriftAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Vol/bind11
Sider (fra-til)301-309
Antal sider9
ISSN2352-8729
DOI
StatusUdgivet - 1 dec. 2019

ID: 57015941